immune checkpoint inhibitor

Goshtaseb R, Luu Y, Sarmosyan K, Lopez L, Drakaki A. Suspected Pembrolizumab-Associated Perinuclear Antineutrophil Cytoplasmic Antibody (p-ANCA) Vasculitis With Progressive Kidney Injury in a Patient[...]

By afschroeder • September 25, 2026

Paniker AG, Marshalek JP, Chao E, Yashar D, Tomassetti S. Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma. J Hematol. 2026 Aug 31;15(4):188-197.[...]

By afschroeder • September 13, 2026

Baclig NV, Chengappa M, Soliman AJ, Jacob S, LeVee A, Fisch S, Face C, Chaudhry S, Idossa D, Poonacha T, Huppert L, Quintal L, Melisko[...]

By afschroeder • August 18, 2026

Lim A, Peluso EM, Downs IA, Horwich BH, Velez-Velez MA, Lechner MG. Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome[...]

By afschroeder • June 11, 2026

Sekhon H, Rajendran PS, Hampilos K, Raddatz MA, Lilley CM, Zinoviev RI, Tai W, Stein-Merlob AF, Fishbein GA, Yang EH. Cardiogenic Shock From Chronic Immune[...]

By afschroeder • March 31, 2026

Chan SL, Finn RS, Edeline J, Ogasawara S, Knox JJ, Daniele B, Ryoo BY, Merle P, Bouattour M, Lim HY, Chao Y, Yau T, Haber[...]

By sjmartinez • December 27, 2025

Johnsen NA, Carlisle R, Baghoomian W, Pierce JL, Nguyen MO. A novel case of acute localized and generalized exanthematous pustulosis following IL-2 analogue injection amplified[...]

By afschroeder • December 10, 2025

Saganty RS, Leiva O, Hutchins E, Stein-Merlob AF, Yang EH. Immune Checkpoint Inhibitor Therapy and Acute Coronary Syndrome: A Review of Mechanisms and Management. J[...]

By afschroeder • November 27, 2025

Wu M, Yang S, Yang Z, Fan J, Lomeli SH, Dharanipragada P, Moriceau G, Damoiseaux R, Kelley MC, Prieto-Granada CN, Giubellino A, Nosrati M, Kashani-Sabet[...]

By afschroeder • November 2, 2025

Zhu L, Cheung YM, Chiang C, Gallagher EJ, Hamnvik OR, Mammen J, Quandt Z, Jones R, McDunn J, Al-Bahadili H, Angell T, Bancos I, Betof[...]

By afschroeder • October 16, 2025